132 related articles for article (PubMed ID: 28971898)
1. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.
Leone G; Tucci M; Buttigliero C; Zichi C; Pignataro D; Bironzo P; Vignani F; Scagliotti GV; Di Maio M
Endocr Relat Cancer; 2018 Jan; 25(1):R1-R9. PubMed ID: 28971898
[TBL] [Abstract][Full Text] [Related]
2. Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
Shiota M; Machidori A; Abe T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Yokomizo A; Naito S; Eto M
Int J Urol; 2020 Dec; 27(12):1109-1115. PubMed ID: 32929792
[TBL] [Abstract][Full Text] [Related]
3. Is there an antiandrogen withdrawal syndrome with enzalutamide?
Rodriguez-Vida A; Bianchini D; Van Hemelrijck M; Hughes S; Malik Z; Powles T; Bahl A; Rudman S; Payne H; de Bono J; Chowdhury S
BJU Int; 2015 Mar; 115(3):373-80. PubMed ID: 24906049
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Paul R; Breul J
Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
[TBL] [Abstract][Full Text] [Related]
5. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
6. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
7. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
8. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS
Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847
[TBL] [Abstract][Full Text] [Related]
9. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Akakura K; Akimoto S; Furuya Y; Ito H
Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
[TBL] [Abstract][Full Text] [Related]
10. Is there an anti-androgen withdrawal syndrome for enzalutamide?
von Klot CA; Kramer MW; Böker A; Herrmann TR; Peters I; Kuczyk MA; Ligges U; Gschwend JE; Retz M; Schmid SC; Stenzl A; Schwentner C; Todenhöfer T; Stöckle M; Ohlmann CH; Azone I; Mager R; Bartsch G; Haferkamp A; Heidenreich A; Piper C; Merseburger AS
World J Urol; 2014 Oct; 32(5):1171-6. PubMed ID: 24691670
[TBL] [Abstract][Full Text] [Related]
11. The antiandrogen withdrawal syndrome.
Wirth MP; Froschermaier SE
Urol Res; 1997; 25 Suppl 2():S67-71. PubMed ID: 9144890
[TBL] [Abstract][Full Text] [Related]
12. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.
Suzuki H; Akakura K; Komiya A; Aida S; Akimoto S; Shimazaki J
Prostate; 1996 Sep; 29(3):153-8. PubMed ID: 8827083
[TBL] [Abstract][Full Text] [Related]
13. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogen withdrawal syndrome with cyproterone acetate.
Sella A; Flex D; Sulkes A; Baniel J
Urology; 1998 Dec; 52(6):1091-3. PubMed ID: 9836560
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for the antiandrogen withdrawal syndrome.
Miyamoto H; Rahman MM; Chang C
J Cell Biochem; 2004 Jan; 91(1):3-12. PubMed ID: 14689576
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer.
Poole A; Gill D; Hahn AW; Johnson E; Carroll E; Boucher K; Nussenzveig R; Maughan B; Agarwal N
Clin Genitourin Cancer; 2017 Sep; ():. PubMed ID: 28958675
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
20. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
